company background image
ITOS

iTeos Therapeutics NasdaqGM:ITOS Stock Report

Last Price

US$18.59

Market Cap

US$660.7m

7D

0.05%

1Y

-16.7%

Updated

22 May, 2022

Data

Company Financials +
ITOS fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends0/6

ITOS Stock Overview

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients.

iTeos Therapeutics Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for iTeos Therapeutics
Historical stock prices
Current Share PriceUS$18.59
52 Week HighUS$52.43
52 Week LowUS$16.36
Beta0
1 Month Change-36.34%
3 Month Change-45.05%
1 Year Change-16.75%
3 Year Changen/a
5 Year Changen/a
Change since IPO-2.42%

Recent News & Updates

May 11
News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

Celebrations may be in order for iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) shareholders, with the analysts delivering a...

Shareholder Returns

ITOSUS BiotechsUS Market
7D0.05%1.4%-2.7%
1Y-16.7%-21.7%-12.9%

Return vs Industry: ITOS exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: ITOS underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is ITOS's price volatile compared to industry and market?
ITOS volatility
ITOS Average Weekly Movement12.3%
Biotechs Industry Average Movement12.4%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market2.9%

Stable Share Price: ITOS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ITOS's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201194Michel Detheuxhttps://www.iteostherapeutics.com

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company’s product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

iTeos Therapeutics Fundamentals Summary

How do iTeos Therapeutics's earnings and revenue compare to its market cap?
ITOS fundamental statistics
Market CapUS$660.70m
Earnings (TTM)US$297.64m
Revenue (TTM)US$497.30m

2.2x

P/E Ratio

1.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ITOS income statement (TTM)
RevenueUS$497.30m
Cost of RevenueUS$0
Gross ProfitUS$497.30m
Other ExpensesUS$199.66m
EarningsUS$297.64m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)8.37
Gross Margin100.00%
Net Profit Margin59.85%
Debt/Equity Ratio0%

How did ITOS perform over the long term?

See historical performance and comparison

Valuation

Is iTeos Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.22x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ITOS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ITOS's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: ITOS is good value based on its PE Ratio (2.2x) compared to the US Biotechs industry average (15.1x).

PE vs Market: ITOS is good value based on its PE Ratio (2.2x) compared to the US market (15.2x).


Price to Earnings Growth Ratio

PEG Ratio: ITOS's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: ITOS is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (1.5x).


Future Growth

How is iTeos Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-44.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ITOS's earnings are forecast to decline over the next 3 years (-44.5% per year).

Earnings vs Market: ITOS's earnings are forecast to decline over the next 3 years (-44.5% per year).

High Growth Earnings: ITOS's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ITOS's revenue is expected to decline over the next 3 years (-23.8% per year).

High Growth Revenue: ITOS's revenue is forecast to decline over the next 3 years (-23.8% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ITOS's Return on Equity is forecast to be high in 3 years time


Past Performance

How has iTeos Therapeutics performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


97.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ITOS has high quality earnings.

Growing Profit Margin: ITOS became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ITOS's earnings have grown significantly by 97.5% per year over the past 5 years.

Accelerating Growth: ITOS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ITOS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: ITOS's Return on Equity (47.5%) is considered outstanding.


Financial Health

How is iTeos Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: ITOS's short term assets ($840.7M) exceed its short term liabilities ($174.3M).

Long Term Liabilities: ITOS's short term assets ($840.7M) exceed its long term liabilities ($49.7M).


Debt to Equity History and Analysis

Debt Level: ITOS is debt free.

Reducing Debt: ITOS has not had any debt for past 5 years.

Debt Coverage: ITOS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ITOS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is iTeos Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ITOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ITOS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ITOS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ITOS's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ITOS has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Michel Detheux (54 yo)

10.75yrs

Tenure

US$5,600,627

Compensation

Dr. Michel Detheux, Ph D, serves as an Independent Chairman at Ona Therapeutics, S.L. since December 2021. He has served as the Chief Executive Officer and Director at iTeos Therapeutics, Inc. since August...


CEO Compensation Analysis

Compensation vs Market: Michel's total compensation ($USD5.60M) is above average for companies of similar size in the US market ($USD3.94M).

Compensation vs Earnings: Michel's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ITOS's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: ITOS's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

iTeos Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: iTeos Therapeutics, Inc.
  • Ticker: ITOS
  • Exchange: NasdaqGM
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$660.702m
  • Shares outstanding: 35.54m
  • Website: https://www.iteostherapeutics.com

Number of Employees


Location

  • iTeos Therapeutics, Inc.
  • 321 Arsenal Street
  • Suite 301
  • Cambridge
  • Massachusetts
  • 02472-5710
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/22 00:00
End of Day Share Price2022/05/20 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.